

## 2019 State Profile — Tennessee

### National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2019 N-SSATS report:

<https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

In Tennessee, 313 substance abuse treatment facilities were included in the 2019 N-SSATS report, which reported a total of 28,899 clients in substance abuse treatment on March 29, 2019. The survey response rate in Tennessee was 98.8 percent.

#### Facility operation, by number and percent

	Clients in treatment on March 29, 2019					
	Facilities		All clients		Clients under the age of 18 years	
	No.	%	No.	%	No.	%
Private non-profit	195	62.3	13,420	46.4	999	82.3
Private for-profit	114	36.4	14,205	49.2	215	17.7
Local, county, or community government	—	—	—	—	—	—
State government	—	—	—	—	—	—
Federal government	4	1.3	1,274	4.4	—	—
Tribal government	—	—	—	—	—	—
<b>Total</b>	<b>313</b>	<b>100.0</b>	<b>28,899</b>	<b>100.0</b>	<b>1,214</b>	<b>100.0</b>

Note: Percentages may not sum to 100 percent due to rounding.

#### Substance abuse problem treated, by number and percent

	Clients in treatment on March 29, 2019				
	Facilities <sup>1</sup>		Clients <sup>2</sup>		Clients <sup>2</sup> per 100,000 pop. aged 18 years or older
	No.	%	No.	%	
Clients with both alcohol and drug abuse	196	82.7	8,087	28.0	140
Clients with drug abuse only	197	83.1	17,857	61.8	328
Clients with alcohol abuse only	152	64.1	2,938	10.2	52
<b>Total</b>			<b>28,883</b>	<b>100.0</b>	<b>520</b>

<sup>1</sup> Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

<sup>2</sup> States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

#### Facility capacity and utilization rate<sup>1</sup>

	Residential	Hospital inpatient
Number of facilities	55	4
Number of clients <sup>2</sup>	1,484	25
Number of designated beds	1,803	40
Utilization rate <sup>3</sup>	82.3	62.5
Average number of designated beds per facility	33	10

<sup>1</sup> Excludes facilities not reporting both client counts and number of beds, facilities whose client counts were reported by another facility, facilities that included client counts from other facilities, and facilities that did not respond to this question.

<sup>2</sup> Number of clients on March 29, 2019.

<sup>3</sup> Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

For a symbol key, see the last page of this profile.

## Type of care, by number and percent

	Clients in treatment on March 29, 2019							
	Facilities		All clients				Clients under the age of 18 years	
	No.	%	No.	%	Median no. of	Median no. of	No.	%
					clients per OTP facility	clients per non-OTP facility		
<b>Outpatient</b>	<b>276</b>	<b>88.2</b>	<b>27,216</b>	<b>94.2</b>	<b>410</b>	<b>22</b>	<b>1,048</b>	<b>86.3</b>
Regular	233	74.4	11,877	41.1	782	15		
Intensive	180	57.5	2,505	8.7	—	12		
Day treatment or partial hospitalization	53	16.9	121	0.4	—	4		
Detoxification	30	9.6	409	1.4	9	15		
Methadone/buprenorphine maintenance or naltrexone treatment	90	28.8	12,304	42.6	405	24		
<b>Residential (non-hospital)</b>	<b>85</b>	<b>27.2</b>	<b>1,568</b>	<b>5.4</b>	<b>83</b>	<b>20</b>	<b>166</b>	<b>13.7</b>
Short term (≤ 30 days)	56	17.9	815	2.8	67	23		
Long term (> 30 days)	76	24.3	584	2.0	—	11		
Detoxification	30	9.6	169	0.6	16	6		
<b>Hospital inpatient</b>	<b>23</b>	<b>7.3</b>	<b>115</b>	<b>0.4</b>	<b>—</b>	<b>6</b>	<b>—</b>	<b>—</b>
Treatment	20	6.4	33	0.1	—	3		
Detoxification	18	5.8	82	0.3	—	5		
<b>Total</b>	<b>313</b>		<b>28,899</b>	<b>100.0</b>	<b>405</b>	<b>24</b>	<b>1,214</b>	<b>100.0</b>

Note: Facilities may provide more than one type of care.

## Facility licensing, certification, or accreditation, by number and percent

	No.	%
Any listed agency/organization	305	97.4
State substance abuse agency	237	75.7
State mental health department	243	77.6
State department of health	85	27.2
Hospital licensing authority	11	3.5
The Joint Commission	83	26.5
Commission on Accreditation of Rehabilitation Facilities (CARF)	90	28.8
National Committee for Quality Assurance (NCQA)	5	1.6
Council on Accreditation (COA)	27	8.6
Healthcare Facilities Accreditation Program (HFAP)	3	1.0
Other national organization or federal, state, or local agency	9	2.9

Note: Facilities may be licensed, certified, or accredited by more than one agency/organization.

## Facility payment options, by number and percent

	No.	%
Cash or self-payment	287	91.7
Private health insurance	233	74.4
Medicare	108	34.5
Medicaid	194	62.0
State-financed health insurance plan other than Medicaid	165	52.7
Federal military insurance	119	38.0
No payment accepted (free treatment for all clients)	14	4.5
IHS/Tribal/Urban (ITU) funds	14	4.5
Other	2	0.6
Sliding fee scale	183	58.5
Treatment at no charge or minimal payment for clients who can't pay	146	46.6

Note: Facilities may accept more than one type of payment.

## Types of services offered, by number and percent

	Facilities	
	No.	%
<b>Assessment and pre-treatment services</b>		
Screening for substance abuse	308	98.4
Screening for mental health disorders	266	85.0
Comprehensive substance abuse assessment or diagnosis	289	92.3
Comprehensive mental health assessment or diagnosis	184	58.8
Screening for tobacco use	212	67.7
Outreach to persons in the community who may need treatment	220	70.3
Interim services for clients when immediate admission is not possible	128	40.9
Professional interventionist/educational consultant	58	18.5
None of these assessment and pre-treatment services offered	3	1.0
<b>Testing</b>		
Drug and alcohol oral fluid testing	61	19.5
Breathalyzer or other blood alcohol testing	171	54.6
Drug or alcohol urine screening	294	93.9
Testing for hepatitis B	69	22.0
Testing for hepatitis C	94	30.0
HIV testing	103	32.9
STD testing	81	25.9
TB screening	202	64.5
Testing for metabolic syndrome	18	5.8
None of these testing services offered	16	5.1
<b>Medical services</b>		
Hepatitis A (HAV) vaccination	35	11.2
Hepatitis B (HBV) vaccination	26	8.3
None of these medical services offered	278	88.8
<b>Transitional services</b>		
Discharge planning	302	96.5
Aftercare/continuing care	291	93.0
Naloxone and overdose education	155	49.5
Outcome follow-up after discharge	219	70.0
None of these transitional services offered	3	1.0
<b>Recovery support services</b>		
Mentoring/peer support	194	62.0
Self-help groups (for example, AA, NA, SMART Recovery)	181	57.8
Assistance in locating housing for clients	189	60.4
Employment counseling or training for clients	131	41.9
Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	174	55.6
Recovery coach	93	29.7
None of these recovery support services offered	28	8.9
<b>Education and counseling services</b>		
HIV or AIDS education, counseling, or support	178	56.9
Hepatitis education, counseling, or support	159	50.8
Health education other than HIV/AIDS or hepatitis	178	56.9
Substance abuse education	309	98.7
Smoking/ tobacco cessation counseling	146	46.6
Individual counseling	306	97.8

Continued

For a symbol key, see the last page of this profile.

**Types of services offered, by number and percent (continued)**

	Facilities	
	No.	%
Group counseling	298	95.2
Family counseling	272	86.9
Marital/couples counseling	195	62.3
Vocational training or educational support	51	16.3
None of these education and counseling services offered	—	—
<b>Pharmacotherapies</b>		
Disulfiram (Antabuse®)	48	15.3
Naltrexone (oral)	101	32.3
Naltrexone (extended-release, injectable, for example, Vivitrol®)	109	34.8
Acamprosate (Campral®)	52	16.6
Nicotine replacement	88	28.1
Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	69	22.0
Medications for psychiatric disorders	174	55.6
Methadone <sup>1</sup>	12	3.8
Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	90	28.8
Buprenorphine without naloxone	59	18.8
Buprenorphine sub-dermal implant (Probuphine®)	3	1.0
Buprenorphine (extended-release, injectable, for example, Sublocade®)	24	7.7
Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	12	3.8
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	18	5.8
Lofexidine	3	1.0
Clonidine	62	19.8
None of these pharmacotherapy services offered	88	28.1
<b>Ancillary services</b>		
Case management services	259	82.7
Social skills development	225	71.9
Child care for clients' children	12	3.8
Domestic violence—family or partner violence services (physical, sexual, and emotional abuse)	123	39.3
Early intervention for HIV	61	19.5
Transportation assistance to treatment	132	42.2
Mental health services	235	75.1
Acupuncture	14	4.5
Residential beds for clients' children	5	1.6
None of these ancillary services offered	24	7.7
<b>Other services</b>		
Treatment for gambling disorder	40	12.8
Treatment for Internet use disorder	29	9.3
Treatment for other addiction disorder (non-substance abuse)	87	27.8
None of these 'other' services offered	219	70.0

<sup>1</sup> Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

**Clinical/therapeutic approaches used frequently, by number and percent**

	Facilities	
	No.	%
Substance abuse counseling	311	99.4
12-step facilitation	230	73.5
Brief intervention	255	81.5
Cognitive behavioral therapy	291	93.0
Dialectical behavior therapy	179	57.2
Contingency management/motivational incentives	147	47.0
Motivational interviewing	283	90.4
Trauma-related counseling	276	88.2
Anger management	256	81.8
Matrix model	155	49.5
Community reinforcement plus vouchers	21	6.7
Rational emotive behavioral therapy (REBT)	124	39.6
Relapse prevention	297	94.9
Telemedicine/telehealth	97	31.0
Other treatment approaches	23	7.3
We do not use any of these clinical/therapeutic approaches	—	—

**Specifically tailored programs or groups, by number and percent**

	Facilities	
	No.	%
Any program or group	235	75.1
Adolescents	63	20.1
Young adults	72	23.0
Adult women	111	35.5
Pregnant or postpartum women	78	24.9
Adult men	109	34.8
Seniors or older adults	64	20.4
LGBT clients	53	16.9
Veterans	58	18.5
Active duty military	36	11.5
Members of military families	41	13.1
Criminal justice clients (other than DUI/DWI)	74	23.6
Clients with co-occurring mental and substance use disorders	168	53.7
Clients with co-occurring pain and substance use	54	17.3
Clients with HIV or AIDS	46	14.7
Clients who have experienced sexual abuse	60	19.2
Clients who have experienced intimate partner violence, domestic violence	58	18.5
Clients who have experienced trauma	89	28.4
DUI/DWI clients	46	14.7
Other	5	1.6
No specifically tailored programs or groups are offered	78	24.9

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBT = lesbian, gay, bisexual, or transgender.

**Facility funding, by number and percent**

	Facilities	
	No.	%
Receives federal, state, county, or local government funds or grants for substance use treatment programs	199	63.6

**Services in sign language for the deaf and hard-of-hearing and in languages other than English, by number and percent**

	Facilities	
	No.	%
Sign language	155	49.5
Any language other than English	195	62.3

**Non-English language provided by**

Staff counselor only	13	6.7
On-call interpreter only	166	85.1
Both staff counselor and on-call interpreter	16	8.2

**Languages provided by staff counselor<sup>1</sup>**

Spanish	26	89.7
American Indian/Alaska Native languages	—	—
Other	7	24.1

<sup>1</sup> Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

**Symbol key (where applicable)**

— Quantity is zero; \* Less than 0.05 percent;  
† Less than 1 per 100,000; ‡ No facilities in this category.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 29, 2019. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: <https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

Access the latest N-SSATS public use files at:  
<https://datafiles.samhsa.gov>

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:  
<https://findtreatment.samhsa.gov/>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Substance Abuse and Mental Health Services Administration  
Center for Behavioral Health Statistics and Quality  
[www.samhsa.gov/data](http://www.samhsa.gov/data)

**Clients receiving medication-assisted opioid therapy (MAOT) at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by number and percent**

	No.	%
<b>Facilities with OTPs<sup>1</sup></b>	<b>13</b>	<b>0.8</b>

**Clients in facilities with OTPs<sup>2</sup>**

Any MAT <sup>3</sup>	6,089	1.4
Methadone	5,566	1.4
Buprenorphine	523	1.5
Naltrexone	—	—

**Clients in facilities without OTPs<sup>4</sup>**


Any MAT <sup>5</sup>	7,476	4.7
Buprenorphine	7,035	5.3
Naltrexone	441	1.6

<sup>1</sup> Percentage of all facilities with OTPs in the U.S. <sup>2</sup> Percentage of all clients receiving methadone, buprenorphine, or naltrexone at facilities with OTPs in the U.S.; see 2019 N-SSATS report for details. <sup>3</sup> Consists of clients receiving methadone, buprenorphine, or naltrexone. <sup>4</sup> Percentage of all clients receiving buprenorphine or naltrexone at non-OTP facilities in the U.S.; see 2019 N-SSATS report for details. <sup>5</sup> Consists of clients receiving buprenorphine or naltrexone.

**Clients per 100,000 population receiving MAOT in OTP facilities on March 29, 2019**

	No.
Any type of medication-assisted therapy <sup>1</sup>	89
Methadone	82
Buprenorphine	8
Naltrexone	—

<sup>1</sup> Includes clients receiving methadone, buprenorphine, or naltrexone.

**Location of treatment facilities**

<https://www.samhsa.gov/data/quick-statistics>